Efficacy and safety of eribulin in the treatment of advanced adult soft tissue sarcoma (STS): First real-world data in Chinese population.

被引：0
|
作者：
Guo, Xi [1 ]
Zhou, Yuhong [1 ]
Zhuang, Rongyuan [1 ]
You, Yang [1 ]
Zhang, Chenlu [1 ]
Wang, Zhiming [1 ]
机构：
[1] Fudan Univ, Zhongshan Hosp, Dept Med Oncol, Shanghai, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
11577
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Beneficial Use of the Combination of Gemcitabine and Dacarbazine in Advanced Soft Tissue Sarcomas: Real-World Data
    Sotes, Ibon Gurruchaga
    Gomez-Mateo, M. Carmen
    Izquierdo, Maria Eugenia Ortega
    Martinez-Trufero, Javier
    CANCERS, 2024, 16 (02)
  • [42] Efficacy and safety of anlotinib hydrochloride in the treatment of advanced bone and soft tissue sarcoma after failure of first-line chemotherapy.
    Yao, Weitao
    Wang, Jiaqiang
    Zhang, Peng
    Wang, Xin
    Yan, Qiang
    Du, Xinhui
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [43] Early experiences in adjuvant treatment of melanoma: Real-world data on tolerability, safety and efficacy
    van Laar, S.
    Kapiteijn, E.
    Gombert, K.
    Guchelaar, H-J.
    Zwaveling, J.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S917 - S917
  • [44] Efficacy and Safety of Axicabtagene Ciloleucel (Axi-cel) for the Treatment of Relapse/Refractory Non-Hodgkin Lymphoma: Real-World Data in Chinese Population
    Yan, Zixun
    Zou, Dehui
    Li, Yuhua
    Zhu, Xiaojian
    Ji, Dongmei
    Qian, Wenbin
    Lu, Ying
    Ji, Chunyan
    Zhou, Keshu
    Jing, Hongmei
    Yang, Hua
    Li, Lanfang
    Li, Fei
    Xu, Kailin
    Niu, Ting
    Wu, Depei
    Hu, Yu
    Zhao, Weili
    BLOOD, 2023, 142
  • [45] Efficacy and safety analysis of Dupilumab for atopic dermatitis of all ages in Chinese population: Real-world data from a single center
    Yang, Zijing
    Wen, Wanting
    Shi, Ruofei
    Chen, Lihong
    Wang, Hailun
    Zheng, Jie
    Zhu, Haiqin
    Pan, Meng
    Zhao, Xiaoqing
    ALLERGY, 2024, 79 (05) : 1379 - 1382
  • [46] Efficacy and Safety of Niraparib as First-Line Maintenance Treatment for Patients with Advanced Ovarian Cancer: Real-World Data from a Multicenter Study in China
    Zhao, Minmin
    Qiu, Shanhu
    Wu, Xin
    Miao, Pengcheng
    Jiang, Zhi
    Zhu, Tao
    Xu, Xizhong
    Zhu, Yanling
    Zhang, Bei
    Yuan, Donglan
    Zhang, Yang
    Sun, Wei
    He, Aiqin
    Zhao, Min
    Hou, Wenjie
    Zhang, Yingli
    Shao, Zhuyan
    Jia, Meiqun
    Li, Mei
    Chen, Jun
    Xu, Jingcheng
    Chen, Bingwei
    Zhou, Ying
    Shen, Yang
    TARGETED ONCOLOGY, 2023, 18 (06) : 869 - 883
  • [47] Efficacy and Safety of Niraparib as First-Line Maintenance Treatment for Patients with Advanced Ovarian Cancer: Real-World Data from a Multicenter Study in China
    Minmin Zhao
    Shanhu Qiu
    Xin Wu
    Pengcheng Miao
    Zhi Jiang
    Tao Zhu
    Xizhong Xu
    Yanling Zhu
    Bei Zhang
    Donglan Yuan
    Yang Zhang
    Wei Sun
    Aiqin He
    Min Zhao
    Wenjie Hou
    Yingli Zhang
    Zhuyan Shao
    Meiqun Jia
    Mei Li
    Jun Chen
    Jingcheng Xu
    Bingwei Chen
    Ying Zhou
    Yang Shen
    Targeted Oncology, 2023, 18 : 869 - 883
  • [48] Efficacy and safety of intravenous paricalcitol treatment in Chinese hemodialysis patients: a real-world database analysis
    Wang, Niansong
    Xie, Yuting
    Jiang, Gengru
    ANNALS OF PALLIATIVE MEDICINE, 2022, 11 (01) : 225 - 239
  • [49] The safety and efficacy of surufatinib for the treatment of advanced neuroendocrine tumors: A prospective, multicenter, real-world study
    Long, J.
    Wu, C.
    Hu, B.
    Tao, C.
    Gu, H.
    Dong, H.
    Yan, J.
    Qi, Z.
    Zhao, C.
    Zhou, J.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S958 - S958
  • [50] The safety and efficacy of cadonilimab in the treatment of advanced and metastatic cervical cancer: A retrospective, real-world study
    Fan, Shi
    Wang, Tao
    Zhang, Qiying
    Wang, Juan
    Su, Jin
    Zhang, Jing
    Wang, Fei
    Liu, Zi
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345